| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
We have developed out original in-house comprehensive genomic profiling (CGP) test and reported the clinical utility of precision medicine for pancreatic cancer. To solve the problem of difficulty in collecting pancreatic tumor samples for genomic analysis, we have developed a novel biopsy method using indocyanine green (ICG) fluorescence imaging as a rapid assessment of collecting tumor samples in performing ultrasound-guided percutaneous biopsy of liver metastases, and investigated the clinical utility of it. Furthermore, we have reported the clinical utility of next-generation sequencing (NGS) for evaluating high microsatellite instability (MSI-H) as a biomarker for immune check point inhibitor.
|
